Experimental Drug Lets B Cells Live And Lymphoma Cells Die
An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology.
Treating Bone Loss In Breast Cancer Survivors: Cancer Drugs Aren't The Only Culprits
Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.
Many breast cancer patients also experience secondary causes of bone loss, such as vitamin D deficiency.
Reactive Oxygen’s Role in Metastasis
Researchers at the Burnham Institute for Medical Research (Burnham) have discovered that reactive oxygen species, such as superoxide and hydrogen peroxide, play a key role in forming invadopodia, cellular protrusions implicated in cancer cell migration and tumor metastasis. Sara Courtneidge, Ph.D., professor and director of the Tumor Microenvironment Program at Burnham’s NCI-designated Cancer Center, and colleagues have found that inhibiting reactive oxygen reduces invadopodia formation and limits cancer cell invasion. The study was published on September 15 in the journal Science Signaling.
Targeted heat therapy offers new standard treatment option for soft tissue sarcoma
Patients with soft-tissue sarcomas at high risk of spreading were 30% more likely to be alive and cancer free almost three years after starting treatment if their tumors were heated at the time they received chemotherapy, according to new research. The finding bolsters the case for intensifying exploration of the strategy in other types of cancer.
Surgical removal of primary tumour improves survival in metastatic breast cancer patients
Removal of the primary breast tumor in women whose cancer has already spread to other parts of the body can have a significant effect on their survival, Dutch researchers have found. Dr Jetske Ruiterkamp, a surgical resident from the Jeroen Bosch Hospital, Den Bosch, The Netherlands, working under the supervision of Dr Miranda Ernst, told Europeís largest cancer congress, ECCO 15 - ESMO 34 in Berlin today, that her research meant that women who were diagnosed at a late stage of the disease could expect to survive longer.